The patent (number EP 3 538 085 B1) was granted on July 12, 2023, and was validated in Spain, France, Germany, Italy, the Netherlands, and the United Kingdom.
Photo © Shutterstock.com/jovan vitanovski
Kemin Industries (Des Moines, IA) has announced that it was granted a patent by the European Patent Office for its proprietary spearmint extract called Neumentix. The patent (number EP 3 538 085 B1) was granted on July 12, 2023, and was validated in Spain, France, Germany, Italy, the Netherlands, and the United Kingdom. The fourth patent filed and granted for the ingredient; it pertains to the ability of the extract to promote the growth of neurons.
The polyphenol-rich extract contains over 50 phenolic compounds, including rosmarinic, salvianolic and lithospermic acids. According to Kemin, Neumentix targets the hippocampus, promoting neurogenesis to supporting one’s ability to learn, manage information, and react.
“Our research has indicated that Neumentix, sourced from patented plants and characterized by its phenolic complex, works to nourish the neurons in the brain and may increase new neural growth in specific areas of the brain, providing an important source of neuronutrition to fuel brain performance in healthy adults.” said Brenda Fonseca, global technical services lead, Kemin Human Nutrition and Health, in a press release. Fonseca is also an inventor listed on the patent.
"Backed by over 19 peer-reviewed scientific publications covering clinical and preclinical research, as well as spearmint plant features, Neumentix is a great choice for manufacturers looking to formulate with safe, sustainable and scientifically backed brain health ingredients to help promote new neuronal growth,” added Fonseca.
DOJ asks Utah court to dismiss FTC lawsuit against Xlear Inc.
March 11th 2025On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”
HHS announces efforts to eliminate independent conclusion of GRAS
Published: March 11th 2025 | Updated: March 11th 2025U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.